

August 5, 2020

OFFICERS

The Hon. Michael N. Castle, Chair The Hon. Kweisi Mfume, Vice Chair * Mary Woolley, President E. Albert Reece, MD, PhD, MBA, Secretary Amy Comstock Rick, JD, Treasurer

BOARD MEMBERS

Tenley E. Albright, MD Georges C. Benjamin, MD Nancy Brown Susan Dentzer Mikael Dolsten, MD, PhD Victor J. Dzau, MD Jay A. Gershen, DDS, PhD The Hon. Bart Gordon William N. Hait, MD, PhD Mary J.C. Hendrix, PhD The Hon, Rush D. Holt, PhD Elizabeth Baker Keffer Debra R. Lappin, JD Alan I. Leshner, PhD James L. Madara, MD Lucinda Maine, PhD, RPh Mark McClellan, MD, PhD Herbert Pardes, MD Sudip S. Parikh, PhD Harold L. Paz, MD, MS Guillermo Prado, PhD Derek Rapp Gary M. Reedy **Laing Rogers** Larry J. Shapiro, MD Deborah Trautman, PhD, RN, FAAN M. Roy Wilson, MD Keith R. Yamamoto, PhD Elias A. Zerhouni, MD

CHAIR EMERITUS

The Hon. John Edward Porter

*on leave of absence

241 18th Street South Suite 501 Arlington, VA 22202 P 703.739.2577 F 703.739.2372

E info@researchamerica.org

The Honorable Mitch McConnell Majority Leader U.S. Senate Washington, D.C. 20510

The Honorable Charles Schumer Minority Leader U.S. Senate Washington, D.C. 20510 The Honorable Nancy Pelosi Speaker of the House U.S. House of Representatives Washington, D.C. 20515

The Honorable Kevin McCarthy Minority Leader U.S. House of Representatives Washington, D.C. 20515

Dear Leader McConnell, Speaker Pelosi, Minority Leader Schumer, and Minority Leader McCarthy:

We greatly appreciate your committed, bipartisan efforts to address both the immediate and long-term impacts of COVID-19. As you negotiate a supplemental spending package to address the complexity of challenges COVID-19 has bred, we urge you to include at least \$26 billion to prevent the pandemic from undercutting the urgently needed medical progress you set in motion when you championed increased funding for NIH, NSF, and other research agencies in Fiscal Year 2020.

COVID-19 has unavoidably derailed research working to find answers in the fight against Alzheimer's disease, cancer, rare diseases, sickle cell anemia, ALS, and numerous other deadly and debilitating health threats. Your leadership and vision are pivotal to ensuring that the pending supplemental spending package replenishes the research funding that COVID-19 has depleted.

By including at least \$26 billion in supplemental research funding, Congress and the Administration can ensure our nation sees the research returns you expected when putting the FY20 budget in place. Those returns – new knowledge that spurs medical, economic, and other key facets of societal progress – have never been more important.

We are thankful for your determination and hard work, as well as those of your respective staff members, and thank you for considering our views.

Sincerely,

Mary Woolley

President and CEO

Marylbolley

Research!America